Pay in 4 interest-free payments of $5.60 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Phase 1b: Multiple Ascending Dose Study (NCT03014609) Study Title: "Safety, Tolerability, PK and PD of Multiple Doses of Cagrilintide in Subjects With Type 2 Diabetes" Status: Completed Phase: Phase 1b Enrollment: 56 participants with T2D Study Period: 2017-2018 Design: Randomized, double-blind, placebo-controlled Duration: 12 weeks Dose Range: 0.3-4.5 mg SC weekly Population: T2D, BMI 25-40, HbA1c 7-10% Key Results: Weight Loss: 6.0 kg (4.5 mg dose) vs
Her expertise and hands-on experience in these areas are instrumental in shaping the content and direction of WholisticResearch, ensuring it remains at the forefront of cognitive enhancement techniques and research.
Like other inflammatory diseases, ulcerative colitis has been linked to oxidative damage and stress
Brown found that the separation of breast cancer cells from the extracellular matrix (ECM) significantly decreased cell viability, whereas cell viability was improved by the ferroptosis inhibitor Fer-1, demonstrating that separation of cells from the ECM is a pro-ferroptosis response
US$ 29.49
US$ 23.41
US$ 23.34
US$ 20.56
US$ 24.69
US$ 21.36
US$ 21.90
